Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J. M. Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, Elena Porro, Luca Giovanella, Peter W. Johnson, Emanuele Zucca

Blood (2018) 132 (2): 179–186.

https://doi.org/10.1182/blood-2018-01-826958

Published: 2018

Includes: Supplemental data

Journal Articles

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Blood (2018) 131 (13): 1456–1463.

https://doi.org/10.1182/blood-2017-07-795476

Published: 2018

Includes: Supplemental data

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Andrei Shustov, MD, Maria Elena Cabrera, Monica Bellei, MSc, PhD, Young Hyeh Ko, MD, Martina Manni, PhD, Steven M. Horwitz, MD, Carmino Antonio De Souza, MD PhD, John A. Radford, MD, Sabela Bobillo Varela, Maria Virginia Prates, MD, Andrés J M Ferreri, MD, Carlos Chiattone, MD, Michele Spina, MD, Julie M. Vose, MDMBA, Annalisa Chiappella, MD, Daniele Laszlo, MD, Dario Marino, MDPhD, Caterina Stelitano, Massimo Federico, MD

Blood (2017) 130 (Supplement 1): 4071.

https://doi.org/10.1182/blood.V130.Suppl_1.4071.4071

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Blood (2017) 130 (Supplement 1): 4072.

https://doi.org/10.1182/blood.V130.Suppl_1.4072.4072

Published: 2017

Journal Articles

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Blood (2017) 130 (Supplement 1): 736.

https://doi.org/10.1182/blood.V130.Suppl_1.736.736

Published: 2017

Journal Articles

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Blood (2017) 130 (Supplement 1): 2008.

https://doi.org/10.1182/blood.V130.Suppl_1.2008.2008

Published: 2017

Journal Articles

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Blood (2017) 130 (Supplement 1): 1512.

https://doi.org/10.1182/blood.V130.Suppl_1.1512.1512

Published: 2017

Journal Articles

The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project

Monica Bellei, Francine M Foss, MD, Steven M Horwitz, MD, Luigi Marcheselli, Won Seong Kim, Maria Elena Cabrera, Ivan Dlouhy, MD, Arnon Nagler, Ranjana H Advani, MD, Emanuela Pesce, Young Hyeh Ko, MD, Virginia Martinez, Silvia Montoto, MD, Carlos Chiattone, Alison J. Moskowitz, MD, Michele Spina, Marina Cesaretti, Irene Biasoli, Massimo Federico

Blood (2016) 128 (22): 921.

https://doi.org/10.1182/blood.V128.22.921.921

Published: 2016

Journal Articles

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Blood (2016) 128 (22): 184.

https://doi.org/10.1182/blood.V128.22.184.184

Published: 2016

Journal Articles

The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry

Irene Biasoli, Marina Cesaretti, Stefano Luminari, Monica Bellei, Alessandra Dondi, Emanuela Anna Pesce, Stefania Badiali, Micol Quaresima, Maria Angela Sirotti, Massimo Federico

Blood (2012) 120 (21): 1611.

https://doi.org/10.1182/blood.V120.21.1611.1611

Published: 2012

Journal Articles

Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

Marc PE André, MD, Oumedaly Reman, MD, Massimo Federico, MD, Théodore Girinski, MD, Pauline Brice, MD, Ercole Brusamolino, MD, Christophe Ferme, MD, Richard vander Maazen, MD, Monica Bellei, Catherine Sebban, MD, Franck Morschhauser, MD, PhD, Elly Lugtenburg, MD, PhD, Aspasia Stamatoulas, MD, Catherine Fortpied, Msc, Michel Meignan, MD, PhD, Annibale Versari, MD, Martin Hutchings, MD, John Raemaekers, MD

Blood (2012) 120 (21): 549.

https://doi.org/10.1182/blood.V120.21.549.549

Published: 2012

Journal Articles

Addition of Rituximab to Front-Line-Treatment Highly Improved the Outcome of Elderly Patients with Follicular Lymphoma: a Population Based-Study From the Modena Cancer Registry

Stefano Luminari, Irene Biasoli, Luigi Marcheselli, Monica Bellei, Alessandra Dondi, Sonia Mastronardi, Marina Cesaretti, Massimo Federico

Blood (2012) 120 (21): 5077.

https://doi.org/10.1182/blood.V120.21.5077.5077

Published: 2012

Journal Articles

Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.

Stefano A. Pileri, MD, Monica Bellei, Julie M Vose, MD, MBA, Joseph M. Connors, MD, Francine M. Foss, MD, Steven M. Horwitz, MD, Silvia Montoto, MD, Aaron Polliack, MD, Pier Luigi Zinzani, MD, Emanuele Zucca, MD, Young-Hyeh Ko, MD, Massimo Federico, MD

Blood (2012) 120 (21): 2650.

https://doi.org/10.1182/blood.V120.21.2650.2650

Published: 2012

Journal Articles

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Blood (2010) 116 (21): 432.

https://doi.org/10.1182/blood.V116.21.432.432

Published: 2010

Journal Articles

Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).

Blood (2009) 114 (22): 3939.

https://doi.org/10.1182/blood.V114.22.3939.3939

Published: 2009

Journal Articles

First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL).

Marc PE André, MD, Oumédaly Reman, MD, Massimo Fédérico, MD, Pauline Brice, MD, Ercole Brusamolino, MD, Théodore Girinski, MD, Christophe Ferme, MD, Richard vander Maazen, MD, Monica Bellei, Catherine Sebban, MD, Franck Morschhauser, MD, PhD, Elly Lugtenburg, MD, Aspasia Stamatoullas, MD, Liliana Baila, MD, MSc, Catherine Fortpied, MSc, Michel Meignan, MD, John M. Raemaekers, MD, PhD

Blood (2009) 114 (22): 97.

https://doi.org/10.1182/blood.V114.22.97.97

Published: 2009

Journal Articles

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

Teodoro Chisesi, MD, Monica Bellei, Stefano Luminari, MD, Luigi Marcheselli, Alessandro Levis, MD, Umberto Vitolo, MD, Caterina Stelitano, MD, Vincenzo Pavone, MD, Francesco Merli, MD, Marina Liberati, MD, Luca Baldini, MD, Roberto Bordonaro, MD, Emanuela Pesce, Paolo Gobbi, MD, Massimo Federico, MD

Blood (2008) 112 (11): 2602.

https://doi.org/10.1182/blood.V112.11.2602.2602

Published: 2008

Journal Articles

Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy

Stefano Luminari, MD, Ivan Rashid, Marina Cesaretti, Luigi Marcheselli, Alessandra Dondi, Stefano Madrigali, Gianluca Cervo, Monica Bellei, Antonella Montanini, Caterina Mammi, Maria Angela Sirotti, Massimo Federico, MD

Blood (2008) 112 (11): 3753.

https://doi.org/10.1182/blood.V112.11.3753.3753

Published: 2008

NARROW

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry

Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

Addition of Rituximab to Front-Line-Treatment Highly Improved the Outcome of Elderly Patients with Follicular Lymphoma: a Population Based-Study From the Modena Cancer Registry

Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only